A recent review published in The Journal of Clinical Investigation suggests that the transition through menopause may mark a critical period for Alzheimer's disease prevention in women, according to findings released on Mar. 18. The review, authored by Dr. Lisa Mosconi, examines how hormonal changes during midlife could influence women's risk for developing Alzheimer's disease.
This topic is important because nearly two-thirds of people affected by Alzheimer's are women, raising questions about why women are more vulnerable to the disease. Traditionally, this has been attributed to longer life expectancy among women, but new evidence points toward biological causes related to hormonal changes during menopause.
The review highlights that menopause involves a significant drop in estrogen levels and increases in follicle-stimulating hormone and luteinizing hormone. Estrogen is known to protect the brain by reducing inflammation and supporting neuronal survival. When estrogen declines during menopause, these protective effects diminish, potentially contributing to processes linked with Alzheimer's development. "Menopause can serve as a biological tipping point in brain aging," Mosconi wrote.
Research cited in the review shows that postmenopausal women have greater amyloid-beta deposition—a key marker of Alzheimer’s—lower cerebral glucose metabolism, and reduced gray matter volume compared with premenopausal women and men. Early menopause or surgical removal of ovaries before natural menopause is also associated with increased dementia risk.
The review discusses other factors such as reproductive history, subjective cognitive decline during perimenopause, and vasomotor symptoms like hot flashes around sleep—all of which may be indicators of elevated Alzheimer’s risk. It also addresses the complex relationship between hormone therapy and dementia: while starting hormone therapy late may increase dementia risk, initiating it near menopause could reduce risk by up to 30%, though these findings require further study due to possible bias.
Mosconi emphasizes that current prevention frameworks often overlook female-specific neuroendocrine and reproductive factors. She concludes that “AD risk in women is likely to be shaped in part by midlife neuroendocrine changes rather than aging alone.” The review calls for more research into sex-specific mechanisms and preventive strategies tailored to women's biology.
